
Covid 19


Course of COVID-19 Infection – A Paradigm for Therapy



ASHD = arteriosclerotic heart disease; Ig = immunoglobulin. Adapted from Calabrese LH. *Cleve Clin J Med.* 2020;87(7):389-393.

Secondary HLH/MAS – Lessons Learned

Cytokine storm/cytokine-release syndrome loosely applies to a wide variety of conditions driven by inflammatory cytokines and immune hyperactivation, triggered by such factors as genetic disorders, cancer, infections, and certain drugs



ARDS = acute respiratory distress syndrome; CRS = cytokine-release syndrome; EBV = Epstein-Barr virus; HLH = hemophagocytic lymphohistiocytosis; MAS = macrophage

Clinical Presentation of Cytokine Storm


COVID-19 "cytokine storm"

- Typically single organ disease (ie, ARDS)
- Multiorgan disease less common
- Elevated cytokines/mediators
- Response to immunomodulatory therapies

Drivers are still unclear

- Virus
- DAMPS
- Genetics
- Comorbidities

DAMPS = damage-associated molecular patterns. Fajgenbaum DC, et al. *N Engl J Med.* 2020;383(23):2255-2273. Image from Bhaskar S, et al. *Front Immunol.* 2020;11:1648. Open access.



Biomarkers in COVID-19

Although inflammatory markers—such as Creactive protein (CRP), D-dimer, and ferritin—are not routinely measured as part of standard care, results from such measurements may have prognostic value²

ALT = alanine aminotransferase; AST = aspartate aminotransferase; CBC = complete blood count; ESR = erythrocyte sedimentation rate; LDH = lactate dehydrogenase.

 Henderson LA, et al. *Arthritis Rheumatol.* 2020;72(7):1059-1063.
 National Institutes of Health. Updated July 24, 2021. Accessed August 19, 2021. https://www.covid19treatmentguidelines.nih.gov/

Biomarkers of CRS and Status in COVID-19¹

Biomarker	Status in hyperinflammation	Status in COVID-19		
CBC	Lymphopenia, neutrophil/lymphocyte	Associated with severity, ARDS		
↑ D-dimer, ↓ fibrinogen	May be indicative of active CRS	Associated with severity, ARDS		
LDH, AST, ALT	May be indicative of active of CRS	Associated with severity, ARDS		
Ferritin	Integral part of CRS diagnosis, predictive of sepsis mortality	Associated with severity, ARDS		
Ferritin:ESR ratio CRP	Higher specificity than ferritin alone	Not assessed		
	Nonspecific, useful for monitoring, blunted by IL-6 blockade	Associated with severity, ARDS		
IL-6	Elevated, nonspecific	Associated with severity		
IFN-y	Elevated, but poor dynamic range	Elevated compared with healthy control		
IL-1β	Elevated, but poor dynamic range	Variably elevated with severity		
IL-18	Very high levels; may indicate MAS, not useful for monitoring	Not assessed		

Current Unresolved Issues in Immunopathogenesis of Severe COVID-19

- Interferon is important in host defense early, but can be deleterious later
- Both genetic and autoimmune factors may contribute to altered function
- Immunologic discordance anatomically (upper/lower respiratory tract) between tissue and blood
- Drivers of SEVERE inflammation may be viral, damage-associated, or both
- Lack of clinically predictive biomarkers or correlates with deep immunologic profiling to guide precision medicine


UPPER AIRWAYS ↑ Type 1/type 3 interferons ↓ COVID-19 severity

SYSTEMIC INFLAMMATION

- ↑ Delayed/prolonged interferons
- ↑ Severe COVID-19
- ↑ Distal tissue damage

Zanoni I. Curr Opin Virol. 2021;50:119-127.

Course of COVID-19 Infection – A Paradigm for Therapy




TIME COURSE

EUA = FDA emergency use authorization; GM-CSF = granulocyte colony-stimulating factor; IFN = interferon; IL = interleukin; JAK = Janus kinase; TNF = tumor necrosis

Severe COVID-19 Clinical Course

Figure. Schematic of Clinical Course of Severe COVID-19

Representation of SARS-CoV-2 RNA levels correlating with infectious replicating virus (shedding of non-infectious viral RNA may persist for a much longer time), common symptoms, and possible timing of therapeutics for the greatest benefit. Duration of symptoms and viral shedding may be prolonged in some patients who are substantially immunocompromised. Below, the red lines illustrate the typical trends for SARS-CoV2 RNA levels in individuals who are and are not immunocompromised. [1]



Johns Hopkins Medicine. Accessed September 8, 2021. https://hopkinsinfectiou sdiseases.jhmi.edu/wpcontent/uploads/2021/0 6/6-9-21_Update_JHMI-Recommendations-for-COVID-19-Therapeutics.pdf

4 Out of 400 Drugs Studied for COVID-19 → Benefit (Endorsed by Professional Societies)

STORM Grades

Dexamethasone

Remdesivir

Tocilizumab

Baricitinib

Castleman Disease Collaborative Network (CDCN). Accessed September 8, 2021. https://cdcn.org/corona-data-viewer/

reatment name to view RCT and Publication Data		Randomized Control Trials			Published Literature	
Search	Grade	ĝ+	# Positive Trials/ Total Completed	# Patients in Completed Trials	# Trials Underway	# Total Uses Recorded
Baricitinib	А		1/1	1,033	10	181
Remdesivir	А		2/4	7,345	38	4,868
Dexamethasone	А		2/2	6,724	34	5,593
Tocilizumab	А		4/10	6,586	56	11,707
Interferon beta 1a (inhaled)	В		1/1	101	7	
Recombinant super-compound interfero.	В		1/1	94		
Novaferon	В		1/1	89	2	52
Interferon beta 1b	В		1/1	80		11,983
Interferon kappa + TFF2	В		1/1	80	1	40
Interferon alpha 2b + interferon gamma	В		1/1	63		
Lopinavir/ritonavir + ribavirin + interfer	В		1/1	86		
Interferon beta 1a (SQ)	В		1/2	4,192	16	11,983
Peginterferon Lambda-1	В		1/2	150		
Colchicine			3/3	243	29	1.493

Note: Order of drugs with same grade does not indicate priority.

See Grading Methods

CORONA Registry

Repurposed Drugs So Much "Promise"... So Little to Show

SAR-CoV-2

- ✓ Hydroxychloroquine
- ✓ Chloroquine
- ✓ Ivermectin
- ✓ Lopinavir/ritonavir
- ✓ Favipiravir
- ✓ Baloxivir
- ✓ Indomethacin
- ✓ Zinc
- ✓ Vitamin C
- ✓ Famotidine





Viral Tissue Culture Studies, in vitro

Human Studies, in vivo


Treatment of COVID-19 (as of October 2, 2021)

- Ambulatory: Monoclonal antibodies
- Hospitalized
 - Not on oxygen: Monoclonal antibodies (if not hospitalized for COVID-19)
 - Oxygen needed: Remdesivir + dexamethasone
 - High flow O₂ or NIV: Remdesivir + dexamethasone
 - Rapid worsening: Tocilizumab or baricitinib
 - IMV or ECMO: Dexamethasone
 - If first 24 hours in ICU: Tocilizumab

NIV = noninvasive ventilation.

Infectious Diseases Society of America. Accessed September 8, 2021. https://www.idsociety.org/practice-guideline/covid-19-guideline-treatmentand-management/; NIH. Updated August 25, 2021. Accessed October 2, 2021. https://www.covid19treatmentguidelines.nih.gov/

NIH Guidelines for Therapeutic Management of Hospitalized Patients



Ritonavir-Boosted Nirmatrelvir (Paxlovid)

In the EPIC-HR trial, ritonavir-boosted nirmatrelvir (Paxlovid) reduced the risk of hospitalization or death by 88% compared to placebo in nonhospitalized adults with laboratory-confirmed SARS-CoV-2 infection.⁸ This efficacy is comparable to the efficacies reported for sotrovimab (i.e., 85% relative reduction),⁹ and remdesivir (i.e., 87% relative reduction)¹⁰ and greater than the efficacy reported for molnupiravir (i.e., 30% relative reduction).¹¹

Ritonavir-boosted nirmatrelvir (Paxlovid) is expected to be active against the Omicron VOC, although in vitro and in vivo data are currently limited.¹² Because of the potential for significant drug-drug interactions with concomitant medications, this regimen may not be a safe choice for all patients (see <u>the</u> <u>Panel's statement on these drug-drug interactions</u> for details).

PATIENT DISPOSITION

Not Requiring Hospitalization or Supplemental Oxygen, As Determined by a Health Care Provider During an ED, In-Person, or Telehealth Visit

PANEL'S RECOMMENDATIONS

Provide symptomatic management for patients who are not at high risk of disease progression.

For patients who are at high risk of progressing to severe COVID-19 (treatments are listed in order of preference, based on efficacy and convenience of use):

- Ritonavir-boosted nirmatrelvir (Paxlovid); or
- Sotrovimab; or
- Remdesivir; or
- Molnupiravir

The Panel recommends against the use of dexamethasone or other systemic glucocorticoids in the absence of another indication (AIII).^a

Discharged From Hospital Inpatient Setting in Stable Condition and Does Not Require Supplemental Oxygen

The Panel recommends against continuing the use of remdesivir (Alla), dexamethasone (Alla), or baricitinib (Alla) after hospital discharge.

Discharged From Hospital Inpatient Setting and Requires Supplemental Oxygen

For those who are stable enough for discharge but who still require oxygen^b There is insufficient evidence to recommend either for or against the continued use of remdesivir, dexamethasone, and/or baricitinib. Review the text below when considering the use of any of these agents after hospital discharge.

Discharged From ED Despite New or Increasing Need for Supplemental Oxygen

When hospital resources are limited, inpatient admission is not possible, and close follow-up is ensured^c The Panel recommends using **dexamethasone** 6 mg PO once daily for the duration of supplemental oxygen (dexamethasone use **should not** exceed 10 days) with careful monitoring for AEs (**BIII**).

There is insufficient evidence to recommend either for or against the use of remdesivir. When considering the use of remdesivir, review the text below for more information.

The Panel recommends against the use of **baricitinib** in this setting, except in a clinical trial (AIII).

Figure 2. Therapeutic Management of Hospitalized Adults With COVID-19 Based on Disease Severity

DISEASE SEVERITY	PANEL'S RECOMMENDATIONS				
Hospitalized but Does Not	The Panel recommends against the use of dexamethasone (Alla) or other corticosteroids (AllI). ^a				
Require Supplemental Oxygen	There is insufficient evidence to recommend either for or against the routine use of remdesivir. For patients at high risk of disease progression, remdesivir may be appropriate.				
	Use 1 of the following options:				
	 Remdesivir^{b,c} (e.g., for patients who require minimal supplemental oxygen) (BIIa) 				
Hospitalized and Requires Supplemental Oxygen	Dexamethasone plus remdesivir ^{b,c} (BIIb) Dexamethasone (BI)				
Supplemental Oxygen	For patients on dexamethasone with rapidly increasing oxygen needs and systemic inflammation, add a second immunomodulatory drug ^d (e.g., baricitinib ^e or tocilizumab ^e) (CIIa) .				
	Use 1 of the following options:				
Hospitalized and Requires Oxygen Through a High-Flow Device or NIV	 Dexamethasone (AI) Dexamethasone plus remdesivir^b (BIII) 				
	For patients with rapidly increasing oxygen needs and systemic inflammation, add either baricitinib ^e (BIIa) or IV tocilizumab ^e (BIIa) to 1 of the 2 options above. ^{d,f}				
	• Dexamethasone (AI) ⁹				
Hospitalized and Requires MV	For patients who are within 24 hours of admission to the ICU:				
or ECMO	Dexamethasone plus IV tocilizumab (Blla)				
	If IV tocilizumab is not available or not feasible to use, IV sarilumab can be used (BIIa).				